

Edgar Filing: ANIKA THERAPEUTICS INC - Form 8-K

ANIKA THERAPEUTICS INC
Form 8-K
July 09, 2002

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (DATE OF EARLIEST EVENT REPORTED): JULY 2, 2002

ANIKA THERAPEUTICS, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

| | | |
|---|--------------------------|--------------------------------------|
| MASSACHUSETTS | 000-21326 | 04-3145961 |
| ----- | ----- | ----- |
| (STATE OR OTHER JURISDICTION OF INCORPORATION) | (COMMISSION FILE NUMBER) | (IRS EMPLOYER IDENTIFICATION NO.) |

236 WEST CUMMINGS PARK, WOBURN, MASSACHUSETTS 01801

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)

(781) 932-6616

(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.

On July 2, 2002, Anika Therapeutics, Inc. (the "Company") selected PricewaterhouseCoopers LLP as its principal independent auditor for the fiscal

Edgar Filing: ANIKA THERAPEUTICS INC - Form 8-K

year ending December 31, 2002. Arthur Andersen LLP served as the Company's principal independent auditor for the fiscal years ended December 31, 2000 and 2001. The decision to engage PricewaterhouseCoopers LLP as the Company's new principal independent auditor was recommended by the Audit Committee and approved by the Company's Board of Directors.

During the fiscal years ended December 31, 2000 and 2001 and the subsequent interim period through June 6, 2002, PricewaterhouseCoopers LLP was not engaged as either the principal accountant to audit the Company's financial statements or as an independent accountant to audit any of the Company's consolidated subsidiaries, nor was PricewaterhouseCoopers LLP consulted by the Company or someone on its behalf with respect to either (i) the application of accounting principles to any specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements or (ii) any matter that was either the subject of a disagreement with Arthur Andersen LLP or any reportable events described in Items 304(a)(2)(i) and 304(a)(2)(ii) of Regulation S-K, respectively.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ANIKA THERAPEUTICS, INC.

Date: July 8, 2002

/s/ Charles H. Sherwood

Charles H. Sherwood
Chief Executive Officer and President